Status:

NOT_YET_RECRUITING

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

Lead Sponsor:

University of Rochester

Conditions:

Abscess

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue a...

Detailed Description

Abscesses form as a result of the interaction between an acute microbial infection and the host immune system, and generally result in fever, nausea, and acute abdominal pain. If untreated, the mortal...

Eligibility Criteria

Inclusion

  • Adults 18 years or older
  • All patients with clinical symptoms (ex: fever, chills, pain, tachycardia, hypotension), laboratory (leukocytosis) and radiologic findings (thick walled, rim-enhancing collection with gas bubbles or air-fluid levels) compatible with an abscess that requires image- guided percutaneous drainage
  • Approval by the primary care team to pursue PDT and discuss enrollment with the patient

Exclusion

  • Pregnancy
  • Lactation
  • Allergy to contrast media, narcotics, sedatives, atropine or eggs
  • Necrotic tissue that requires surgical debridement
  • Severely compromised cardiopulmonary function or hemodynamic instability
  • Thrombocytopenia (\<50,000/mm3)
  • Uncorrectable coagulopathy
  • Poor kidney function (serum creatinine \>3mg/dl)
  • Lack of a safe pathway to the abscess or fluid collection
  • Unable or unwilling to understand or to provide informed consent
  • Unable or unwilling to undergo study procedures
  • Patient unable to cooperate with, or to be positioned for the procedure
  • Unable to comply with necessary follow up
  • Patients with pancreatic abscesses
  • Patients with known fistulous communication with their abscess
  • Abscess greater than 13 cm in diameter

Key Trial Info

Start Date :

December 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 15 2030

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT06052956

Start Date

December 15 2025

End Date

November 15 2030

Last Update

August 11 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Highland Hospital

Rochester, New York, United States, 14620

2

University of Rochester Medical Center

Rochester, New York, United States, 14642